title: CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.
abstract: The aim of this study was to examine TOP2A gene copy number changes as a means to identify groups of breast cancer patients with superior benefit from treatment with anthracyclines. Tumour tissue was retrospectively collected and successfully analysed for TOP2A in 773 of 980 Danish patients randomly assigned to receive intravenous CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil) in DBCG trial 89D. Subgroup analyses on this material published by Knoop et al. (J Clin Oncol 23:7483-7490, 2005) and updated by Nielsen et al. (Acta Oncol 47:725-734, 2008) demonstrated that superiority of CEF over CMF is limited to patients with TOP2A aberrations, defined as patients whose tumours have TOP2A ratio below 0.8 or above 2.0. The Subpopulation Treatment Effect Pattern Plot (STEPP) technique was applied to these data to explore the pattern of treatment effect relative to TOP2A and to compare that pattern to the ranges previously used to define 'aberrations'. The pattern of treatment effect illustrated by the STEPP analysis confirmed that the superiority of CEF over CMF is indeed limited to patients whose tumours have high or low TOP2A ratios. The hypothesis of no treatment effect-covariate interaction was rejected (P = 0.02). Furthermore, results indicated that the interval of TOP2A ratios hitherto denoted as 'normal' could be narrower than previously assumed. A more optimal separation of TOP2A subgroups could be obtained by altering cut-points currently used to define TOP2A amplified and TOP2A deleted tumours by narrowing the TOP2A normal interval, and consequently enlarging the population with TOP2A aberrated tumours.
authors.affiliation: Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet, Bldg 2501 9, Blegdamsvej, 2100 Copenhagen, Denmark.
authors.forename: Katrín A
authors.initials: KA
authors.lastname: Gunnarsdóttir
authors.forename: Maj-Britt
authors.initials: MB
authors.lastname: Jensen
authors.forename: David
authors.initials: D
authors.lastname: Zahrieh
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.forename: Ann
authors.initials: A
authors.lastname: Knoop
authors.forename: Marco
authors.initials: M
authors.lastname: Bonetti
authors.forename: Henning
authors.initials: H
authors.lastname: Mouridsen
authors.forename: Bent
authors.initials: B
authors.lastname: Ejlertsen
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D002945:Cisplatin; D003520:Cyclophosphamide / Q000008:administration & dosage; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D018628:Gene Dosage; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008727:Methotrexate / Q000008:administration & dosage; D000075223:Poly-ADP-Ribose Binding Proteins; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D015251:Epirubicin; D003520:Cyclophosphamide; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate
references.citation: Lancet Oncol. 2010 Mar;11(3):266-74
references.pmid: 20079691
references.citation: Acta Oncol. 2008;47(4):725-34
references.pmid: 18465341
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7483-90
references.pmid: 16234514
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5027-35
references.pmid: 18768436
references.citation: N Engl J Med. 2006 Nov 2;355(18):1851-62
references.pmid: 17079759
references.citation: J Clin Oncol. 1998 Aug;16(8):2651-8
references.pmid: 9704715
references.citation: Eur J Cancer. 2007 Mar;43(5):877-84
references.pmid: 17306974
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3430-6
references.pmid: 19470942
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2428-36
references.pmid: 16682728
references.citation: Stat Med. 2009 Apr 15;28(8):1255-68
references.pmid: 19170050
references.citation: Acta Oncol. 2004;43(1):35-42
references.pmid: 15068318
references.citation: J Clin Oncol. 2005 Nov 20;23(33):8313-21
references.pmid: 16293862
references.citation: Am J Pathol. 2000 Mar;156(3):839-47
references.pmid: 10702400
references.citation: J Clin Oncol. 2009 Aug 20;27(24):3881-6
references.pmid: 19620488
references.citation: J Clin Oncol. 1996 Jan;14(1):35-45
references.pmid: 8558217
references.citation: Ann Oncol. 2003 Jun;14(6):833-42
references.pmid: 12796019
references.citation: Biostatistics. 2004 Jul;5(3):465-81
references.pmid: 15208206
references.citation: J Clin Oncol. 1990 Sep;8(9):1483-96
references.pmid: 2202791
references.citation: Stat Med. 2000 Oct 15;19(19):2595-609
references.pmid: 10986536
references.citation: J Natl Cancer Inst. 2009 May 6;101(9):644-50
references.pmid: 19401546
references.citation: Clin Cancer Res. 2002 May;8(5):1107-16
references.pmid: 12006526
references.citation: Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3231-5
references.pmid: 8386368